Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.62 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.62 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | GAA | P10253 | 2/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.58 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.52 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.52 |
| ▸ | ANPEP | P15144 | 1/20 | 0.52 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | NSD2 | O96028 | 1/20 | 0.50 |
| ▸ | GRK2 | P25098 | 1/20 | 0.50 |
| ▸ | CASP6 | P55212 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL11146854 | 0.98 | CA2 (0.60) | CA2CAMK2AAKR1B1LMNAGAA | |
| Hydrochloric Acid SCHEMBL2575898 | 0.98 | CA2 (0.60) | CA2CAMK2AAKR1B1LMNAGAA | |
| SCHEMBL11136721 | 0.93 | CA2 (0.56) | CA2CAMK2AAKR1B1LMNAGAA | |
| SCHEMBL11135171 | 0.89 | SRD5A2 (0.59) | CA2CAMK2AAKR1B1LMNAGAA | |
| Hydrochloric Acid SCHEMBL11134658 | 0.88 | SRD5A2 (0.57) | CA2CAMK2AAKR1B1LMNAGAA | |
| SCHEMBL69614 | 0.87 | CA2 (0.79) | CA2CAMK2AAKR1B1LMNAGAA | |
| SCHEMBL11134156 | 0.86 | CA2 (0.48) | CA2CAMK2AAKR1B1LMNAGAA | |
| Glycine SCHEMBL2596528 | 0.84 | GLRA1 (0.56) | CA2TSHRKDM4EABATSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL25180348 | 0.84 | CA2 (0.75) | CA2CAMK2AAKR1B1LMNAGAA | |
| Hydrochloric Acid SCHEMBL6765874 | 0.84 | CA2 (0.75) | CA2CAMK2AAKR1B1LMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 378 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4619050-A2 | DECREASED RETENTION OF MINIPROTEINS IN KIDNEY | Aktis Oncology, Inc. (US) | 2025-09-24 | — | — | EP | claimed |
| US-20250111889-A1 | DE NOVO DESIGNED MACROCYCLIC OLIGOAMIDES | UNIVERSITY OF WASHINGTON | 2025-04-03 | — | — | US | claimed |
| EP-4463155-A2 | DE NOVO DESIGNED MACROCYCLIC OLIGOAMIDES | University of Washington (US) | 2024-11-20 | — | — | EP | claimed |
| CN-118084965-B | Long-acting phosphorus hapten, antigen, antibody, detection device and preparation and application thereof | 广州科技贸易职业学院 | 2024-06-25 | — | — | CN | claimed |
| CN-118084965-A | Long-acting phosphorus hapten, antigen, antibody, detection device and preparation and application thereof | 广州科技贸易职业学院 | 2024-05-28 | — | — | CN | claimed |
| WO-2024107762-A2 | DECREASED RETENTION OF MINIPROTEINS IN KIDNEY | AKTIS ONCOLOGY, INC. (US) | 2024-05-23 | — | — | WO | claimed |
| CN-116813497-B | Amide compound and preparation method, pharmaceutical composition and application thereof | 天津匠新致成科技有限公司 | 2023-11-14 | — | — | CN | claimed |
| WO-2023137366-A2 | DE NOVO DESIGNED MACROCYCLIC OLIGOAMIDES | UNIVERSITY OF WASHINGTON (US) | 2023-07-20 | — | — | WO | claimed |
| US-20260116923-A1 | CYCLIC PEPTIDE IL-1BETA TRAP FOR THE TREATMENT OF ATHEROSCLEROSIS AND INFLAMMATORY DISORDERS | MERCK SHARP & DOHME LLC (US) | 2026-04-30 | — | — | US | disclosed |
| EP-3697208-B1 | HIGH-FIDELITY LONG-TERM STORAGE OF BIOLOGICAL MATERIAL | CENTRE NAT RECH SCIENT (FR) | 2026-04-22 | — | — | EP | disclosed |
| EP-4687443-A1 | METHOD FOR FUNCTIONALISING A SOLID SUBSTRATE WITH A PEPTIDE CONJUGATE | Genepep (FR) | 2026-02-11 | — | — | EP | disclosed |
| EP-3966226-B1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | BAYER AG (DE) | 2025-12-24 | — | — | EP | disclosed |
| US-12503491-B2 | MASP inhibitory compounds and uses thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2025-12-23 | — | — | US | disclosed |
| EP-4619050-A2 | DECREASED RETENTION OF MINIPROTEINS IN KIDNEY | Aktis Oncology, Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| EP-0386839-A2 | Tetrahydroquinoline derivatives useful for neurodegenerative disorders | MERCK SHARP & DOHME LTD. (GB) | 1990-09-12 | — | — | EP | disclosed |
| US-4297489-A | CEPHALOSPORINS | BRISTOL-MYERS COMPANY (US) | 1981-10-27 | — | — | US | disclosed |
| US-4179511-A | Antibacterial 3-(5-tetrazolyl) penam compounds | PFIZER INC. (US) | 1979-12-18 | — | — | US | disclosed |
| US-4143039-A | ANTIBACTERIAL 3-(5-TETRAZOLYL)PENAM COMPOUNDS | PFIZER INC. (US) | 1979-03-06 | — | — | US | disclosed |
| US-4115385-A | PENICILLINS | PFIZER INC. (US) | 1978-09-19 | — | — | US | disclosed |
| US-3996201-A | MOLDING | CIBA-GEIGY CORPORATION (US) | 1976-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12503491-B2 | MASP inhibitory compounds and uses thereof | MASP2, SERPINB1, SPINT2 | CA2 3928/4885CAMK2A 2231/4885AKR1B1 1714/4885 |
| US-20250111889-A1 | DE NOVO DESIGNED MACROCYCLIC OLIGOAMIDES | DHFR, CCNH, ODC1 | CA2 4658/4885CAMK2A 4398/4885AKR1B1 3107/4885 |
| US-20260116923-A1 | CYCLIC PEPTIDE IL-1BETA TRAP FOR THE TREATMENT OF ATHEROSCLEROSIS AND INFLAMMATORY DISORDERS | IL1A, IL1B, IL1RN | CA2 4115/4885CAMK2A 1733/4885AKR1B1 1592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.